Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Mirrx, Monsanto, and More

Premium

Title: Inhibition of Versican with siRNA and Other Molecules

Patent Number: 8,410,067

Filed: Oct. 31, 2008

Lead Inventor: Thomas Wight, Benaroya Research Institute

The invention, the patent’s abstract states, provides “methods of treating disease or condition in a subject in need thereof … [involving] administering the subject a versican inhibitor in an amount effective to treat the disease or condition. Example diseases or conditions include, but are not limited to, fibrotic disease such as fibrotic lung disease, restenosis such as arterial restenosis, atherosclerosis, cancer, and inflammatory disease. Compounds and compositions for carrying out such a method are also described.”


Title: Oligoribonucleotide Inhibitors of Nrf2 and Methods of Use Thereof for Treatment of Cancer

Patent Number: 8,410,069

Filed: Oct. 8, 2010

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

“The invention provides novel double-stranded oligoribonucleotides that inhibit the Nrf2 gene,” the patent’s abstract states. “The invention also provides a pharmaceutical composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The … invention also relates to methods and compositions for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.”


Title: Methods and Compositions for Prevention or Treatment of RSV Infection

Patent Number: 8,410,073

Filed: Jan. 26, 2012

Lead Inventor: Akshay Vaishnaw, Alnylam Pharmaceuticals

The patent, its abstract states, claims “methods and compositions … for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets.”


Title: Double-Stranded RNA Oligonucleotides Which Inhibit Tyrosinase Expression

Patent Number: 8,410,260

Filed: Oct. 15, 2008

Lead Inventor: Christine Djangone-Collin, L’Oreal

“Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications … and can be associated with cationic particles,” the patent’s abstract states.


Title: Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus

Patent Number: 8,410,261

Filed: Oct. 4, 2011

Lead Inventor: Pamela Tan, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the JC virus, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length … and which is substantially complementary to at least a part of a gene from the JC virus,” according to the patent’s abstract. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC virus in a cell.”


Title: Invertebrate microRNAs

Patent Number: 8,410,334

Filed: Feb. 19, 2008

Lead Inventor: Edwards Allen, Monsanto

“This invention provides a non-natural transgenic plant cell expressing at least one invertebrate miRNA in planta for suppression of a target gene of an invertebrate pest or of a symbiont associated with the invertebrate pest; recombinant DNA constructs for expression of at least one invertebrate miRNA in planta and methods of use thereof; [and] a non-natural transgenic plant containing the non-natural transgenic plant cell of this invention,” according to the patent’s abstract. Also claimed is a “non-natural transgenic plant grown from the non-natural transgenic plant cell of this invention, and non-natural transgenic seed produced by the non-natural transgenic plants, as well as commodity products produced from a non-natural transgenic plant cell, plant, or seed of this invention.”


Title: Double-Stranded RNA Constructs to Control Ants

Application Number: 20130078212

Filed: Sept. 11, 2012

Lead Inventor: Liming Zhao, US Department of Agriculture

The patent application, its abstract states, claims “double-stranded RNA constructs used to … induce mortality in ants classified in the Formicidae family.”


Title: Novel shRNA Molecules and Methods of Use Thereof

Application Number: 20130078719

Filed: June 29, 2012

Inventor: Donald Rao, Gradalis

The invention, the patent application’s abstract states, relates to “certain novel shRNA molecules and methods of use thereof. … Methods for reducing the expression level of a target gene are provided … [including those involving administering] a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double-stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double-stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.”


Title: Methods and Compositions for Modulating Gene Expression Using Oligonucleotide-Based Drugs Administered In Vivo or In Vitro

Application Number: 20130079382

Filed: Dec. 3, 2010

Inventor: Larry Smith, Smith Holdings

The patent application, its abstract states, claims “compositions and methods for down-modulating target gene expression with RNA interference, as well as methods for administering said compositions. … The method comprises administering a first strand to a cell, incubating the cell for a time period suitable for uptake of the first oligo prior to administering a second strand, wherein the first strand and said second strand form an intracellular duplex which is effective to catalyze degradation of gene target mRNA or inhibit translation of said mRNA.”


Title: siRNA and Their Use in Methods and Compositions for the Treatment and/or Prevention of Eye Conditions

Application Number: 20130079389

Filed: May 27, 2011

Lead Inventor: Marta Fraga-Lopez, Sylentis

The invention, the patent application’s abstract states, “relates to methods and compositions for the treatment/and or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor.”


Title: Bivalent Antisense Oligonucleotides

Application Number: 20130079505

Filed: March 24, 2011

Lead Inventor: Thorleif Moller, Mirrx Therapeutics

The invention, the patent application’s abstract states, “provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or [a] microRNA.”

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.